Capecitabine-induced cardiotoxicity: when to suspect? How to manage? A case report.
We present a case of capecitabine-induced cardiac toxicity manifested by chest pain, ST-segment elevation and ventricular tachycardia. Symptoms and ECG alterations were completely reversible after withdrawal of the drug. Coronary angiography demonstrated the absence of epicardial coronary spasm. We suggest cardiac monitoring with ECG Holter and effort ECG during the first days of drug administration. Prompt evaluation of chest pain in this setting is of paramount importance.
Farina
Andrea
A
Cardiology Division, Cardiovascular Department, A. Manzoni Hospital, Lecco, Italy. a.farina@ospedale.lecco.it
Malafronte
Cristina
C
Valsecchi
Maria Antonia
MA
Achilli
Felice
F
D000787:Angina Pectoris / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D017023:Coronary Angiography; D003329:Coronary Vasospasm / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D004110:Diltiazem / Q000627:therapeutic use; D004562:Electrocardiography; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D017180:Tachycardia, Ventricular / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D014665:Vasodilator Agents / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D014665:Vasodilator Agents; D003841:Deoxycytidine; D000069287:Capecitabine; D004110:Diltiazem; D005472:Fluorouracil